Regulation of E-cadherin expression by VHL and hypoxia-inducible factor

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3567-3575

  Esteban, Miguel A ^a   Tran, Maxine G B ^a   Harten, Sarah K ^a   Hill, Peter ^a   Castellanos, Maria C ^c   Chandra, Ashish ^b   Raval, Raju ^d   O'Brien, Tim S ^b   Maxwell, Patrick H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Henry Wellcome Building of Genomic Medicine ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; VON HIPPEL LINDAU DISEASE;

ADULT; CADHERINS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FEMALE; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; KIDNEY TUBULES; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RNA, MESSENGER; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33645748171     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2670     Document Type: Article

References (36)

1. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-82.
2. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
4. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
5. Poellinger L, Johnson RS. HIF-1 and hypoxic response: the plot thickens. Curr Opin Genet Dev 2004;14:81-5.
6. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
7. Barry RE, Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004;10:466-72.
8. Bishop T, Lau KW, Epstein AC, et al. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol 2004;2:e289.
9. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 2002;62:2929-36.
10. Kamada M, Suzuki K, Kato Y, Okuda H, Shuin T. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res 2001;61:4184-9.
11. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
12. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.
13. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3:155-66.
14. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
15. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002;109:987-91.
16. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori GA. causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
17. Bienz M. beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 2005;15:R64-7.
18. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
20. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
21. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003;63:6130-4.
22. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
23. Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-38.
24. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-68.
25. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME. Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993;44:147-58.
26. Hoffman MA, Ohh M, Yang H, Kclo JM, Ivan M, Kaelin WG, Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-27.
27. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155-67.
28. Aprelikova O, Chandramouli GV, Wood M, et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem 2004;92:491-501.
29. Grone HJ, Weber K, Helmchen U, Osborn M. Villin: a marker of brush border differentiation and cellular origin in human renal cell carcinoma. Am J Pathol 1986;124:294-302.
30. Cao Y, Karsten U, Zerban H, Bannasch P. Expression of MUCl, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch 2000;436:119-26.
31. Nojima D, Nakajima K, Li LC, et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001;32:19-27.
32. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001;21:865-74.
33. Vernon AE, LaBonne C. Tumor metastasis: - new twist on epithelial-mesenchymal transitions. Curr Biol 2004;14:R719-21.
34. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2:84-9.
35. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
36. Imai T, Horiuchi A, Wang C, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003;163:1437-47.